DXR (Daxor Corporation) חוב לטווח קצר של החברה

Patents for radioisotope analysis create an insurmountable barrier for competitors, while at GURU.Markets, the amount of short-term borrowed capital is compared with real liquidity, where the value of 0.00 records the metric level. The development of BVA-100 systems and new analyzers confirms technological progress. Daxor Corporation (DXR) is guaranteed absolute market monopoly by its status as the sole FDA-approved manufacturer of blood volume measurement equipment.

To minimize fundamental risks, investors should select assets with a controlled volume of liabilities due within one year. The book value of short-term debt consolidates all current liabilities, serving as an indicator of liquidity and the ability of Daxor Corporation (DXR) to finance costly developments of new blood analysis standards while maintaining robotic production lines, as clearly reflected in the price action of this chart.